ANAB — AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 136
- Website: https://www.anaptysbio.com
Latest SEC filings for ANAB
- ARS — 2026-06-29
- 8-K — 2026-06-22
- 8-K — 2026-05-29
- 8-K — 2026-05-21
- 10-Q — 2026-05-12
- 8-K — 2026-05-12
- 8-K — 2026-05-11
- 10-K/A — 2026-04-28
- 8-K/A — 2026-04-24
- 8-K — 2026-04-20
Latest ANAB news
- — AnaptysBio quickly drops amid hearing on GSK/Tesaro contract breach (seekingalpha_market)
- — Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer (GlobeNewswire Inc.)
- — AnaptysBio gains as GSK granted FDA label expansion for Jemperli (seekingalpha_market)
Educational tool only — not investment advice.